A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

This study is testing a new drug called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS) — a form of MS where symptoms come and go in episodes called relapses. Researchers want to find out if BCD-281 is safe and effective at reducing relapses and new brain lesions. **You may be eligible if...** - You are 18–55 years old - You have been diagnosed with relapsing-remitting MS - You have had at least 1 relapse in the last 12 months, or 2 relapses in the last 2 years, or had a recent active brain lesion on MRI - Your MS disability score is mild to moderate (EDSS 0–5.5) - You have immunity to chickenpox (varicella-zoster virus) - You are willing to stop your current MS medications **You may NOT be eligible if...** - You have primary or secondary progressive MS - You have had MS for over 10 years with only very mild disability - You have a serious infection or immune-suppressing condition - You cannot get an MRI - You are pregnant or unwilling to use contraception Talk to your doctor to see if this trial is right for you.